Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.
Pulse Biosciences (NASDAQ:PLSE) used its fourth-quarter and full-year 2025 earnings call to outline progress across its ...
5d
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data ...
Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in presentations and in a live case transmission “We are gaining significant momentum generating clinical and preclinical ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Hosted on MSN
Pulse Biosciences targets Q1 completion of PRECISE-BTN study enrollment as clinical adoption grows
CEO Paul LaViolette highlighted significant momentum across Pulse Biosciences’ three market development programs, emphasizing early adoption and progress in clinical trials. LaViolette stated, "We are ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...
Pulse Biosciences (NASDAQ:PLSE) will release its quarterly earnings report on Thursday, 2026-02-19. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Pulse ...
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results